The purpose of this observational study is to evaluate the effectiveness and tolerability of outpatient titration regimen with OxyContin as background for moderate and severe pain in cancer patients in adult patients with moderate to severe cancer pain. The main questions it aims to answer are
* To evaluate the effectiveness of titration regimen with OxyContin as background for the moderate and severe pain in cancer participants * To explore the tolerability of titration regimen with OxyContin as background use in outpatient participants with moderate and severe cancer pain
Male or female cancer participants, age ≥ 18 years
Participants presenting with moderate to severe (NRS ≥ 4 points) cancer-related pain
Participants undergoing outpatient titration regimen with OxyContin as background, see Appendix 3
Voluntarily sign an informed consent form
Participants with cognitive impairment, delirium, psychiatric disorders, or other conditions that may interfere with reliable pain self-assessment
Participants are receiving surgery or minimally invasive interventional pain management
Participants are not willing to cooperate in completing follow-up
The investigator judges as unsuitable for inclusion in the study
Adult patients with moderate-to-severe cancer pain treated with the outpatient OxyContin dose titration regimen，able to complete questionnaire and scale assessments.
Cohort
Prospective
Not listed
The proportion of participants achieving pain relief after treatment.
Pain assessments will be performed using the BPI-SF (Brief Pain Inventory-Short Form) and NRS (Numerical Rating Scale). The proportion of participants achieving pain remission, which is defined as the rate of participants with average NRS (Numerical rating scale) score ≤3 \[CR (Complete remission)\] or achieving a reduction of 25% when NRS score \>3 \[PR (Partial remission)\] at 72 h
Adverse events: the frequency and severity of adverse events
assessed primarily by adverse events occurring after treatment (defined as adverse events that emerge or worsen following the first dose of OxyContin), and may also be evaluated via physical examinations and vital signs.
Click on the lead sponsor to view all of their trials.
Mundipharma (China) Pharmaceutical Co. Ltd
Lead sponsor
Tigermed Consulting Co., Ltd
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
